文献速递心脑血管急症重症综合管理与镇静镇痛

艾司洛尔早期静脉β受体阻滞治疗成人重型颅脑创伤:2a期干预设计研究

Early Intravenous Beta-Blockade with Esmolol in Adults with Severe Traumatic Brain Injury: A Phase 2a Intervention Design Study.
PubMed 文献 · Neurocrit Care · 2024-06-28
一句话结论重型颅脑创伤后24小时内以艾司洛尔将心率较基线降低15%、维持脑灌注压>60 mmHg,起始10 μg/kg/min、每30分钟递增5 μg/kg/min的方案剂量限制性毒性概率低(7%)。

本研究为单中心、开放标签、基于自适应模型设计的剂量探索研究,纳入16例18岁以上重型颅脑创伤并接受颅内压监测的成人,伤后24小时内给予艾司洛尔,目标为心率较前4小时基线降低15%,同时保证脑灌注压维持在60 mm Hg以上。按每3例一组、无剂量限制性毒性时按预设方案递增起始剂量与剂量增量。主要终点为最大耐受剂量方案,定义为剂量限制性毒性概率低于10%;结果显示最佳起始剂量为10 μg/kg/min、每30分钟递增5 μg/kg/min,该方案估计剂量限制性毒性概率为7%。6个月全因死亡率为12.5%(标准化死亡比0.63),出现1例剂量限制性毒性事件,无严重不良血流动力学效应。作者认为以心率降低15%为目标滴定的艾司洛尔在重型颅脑创伤后24小时内可行。

要点

  • 纳入16例重型颅脑创伤成人(女性6例[37.5%],平均年龄36岁[标准差13岁],格拉斯哥昏迷评分中位数6.5分[四分位距5-7]),伤后24小时内给予艾司洛尔。
  • 最佳起始剂量为10 μg/kg/min,每30分钟递增5 μg/kg/min,为估计剂量限制性毒性概率低于10%的最高剂量(7%)。
  • 滴定目标为心率较前4小时基线降低15%,同时脑灌注压维持在60 mm Hg以上;剂量限制性毒性定义为未能维持脑灌注压而触发停止艾司洛尔输注。
  • 6个月全因死亡率为12.5%(标准化死亡比0.63);出现1例剂量限制性毒性事件,无严重不良血流动力学效应。

适用人群与场景

  • 18岁及以上成人重型颅脑创伤并接受颅内压监测者,伤后24小时内开始给予艾司洛尔。

诊断标准与关键阈值

  • 剂量限制性毒性定义为未能维持脑灌注压而触发停止艾司洛尔输注。
  • 滴定目标为心率较前4小时基线降低15%,同时脑灌注压维持在60 mm Hg以上。

处置流程与药物剂量

  • 艾司洛尔起始剂量10 μg/kg/min,每30分钟递增5 μg/kg/min,目标为心率较前4小时基线降低15%,同时脑灌注压维持在60 mm Hg以上。
  • 按每3例一组、无剂量限制性毒性时按预设方案递增起始剂量与剂量增量。

红旗征与不能漏的情况

  • 未能维持脑灌注压即触发停止艾司洛尔输注(剂量限制性毒性)。

研究设计与关键结果

  • 单中心、开放标签、基于自适应模型设计的剂量探索研究,纳入16例患者(女性6例[37.5%],平均年龄36岁[标准差13岁],格拉斯哥昏迷评分中位数6.5分[四分位距5-7])。
  • 最佳起始剂量为10 μg/kg/min、每30分钟递增5 μg/kg/min,估计剂量限制性毒性概率为7%(低于10%)。
  • 6个月全因死亡率为12.5%,标准化死亡比为0.63;出现1例剂量限制性毒性事件,无严重不良血流动力学效应。

证据类型、等级与局限

  • 2a期干预设计研究(单中心、开放标签、基于自适应模型设计的剂量探索研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为以心率降低15%为目标滴定的艾司洛尔在重型颅脑创伤后24小时内可行;使用优化方案时需停用艾司洛尔的剂量限制性毒性概率低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Targeted beta-blockade after severe traumatic brain injury may reduce secondary brain injury by attenuating the sympathoadrenal response. The potential role and optimal dosage for esmolol, a selective, short-acting, titratable beta-1 beta-blocker, as a safe, putative early therapy after major traumatic brain injury has not been assessed.

METHODS: We conducted a single-center, open-label dose-finding study using an adaptive model-based design. Adults (18 years or older) with severe traumatic brain injury and intracranial pressure monitoring received esmolol within 24 h of injury to reduce their heart rate by 15% from baseline of the preceding 4 h while ensuring cerebral perfusion pressure was maintained above 60 mm Hg. In cohorts of three, the starting dosage and dosage increments were escalated according to a prespecified plan in the absence of dose-limiting toxicity. Dose-limiting toxicity was defined as failure to maintain cerebral perfusion pressure, triggering cessation of esmolol infusion. The primary outcome was the maximum tolerated dosage schedule of esmolol, defined as that associated with less than 10% probability of dose-limiting toxicity. Secondary outcomes include 6-month mortality and 6-month extended Glasgow Outcome Scale score.

RESULTS: Sixteen patients (6 [37.5%] female patients; mean age 36 years [standard deviation 13 years]) with a median Glasgow Coma Scale score of 6.5 (interquartile range 5-7) received esmolol. The optimal starting dosage of esmolol was 10 μg/kg/min, with increments every 30 min of 5 μg/kg/min, as it was the highest dosage with less than 10% estimated probability of dose-limiting toxicity (7%). All-cause mortality was 12.5% at 6 months (corresponding to a standardized mortality ratio of 0.63). One dose-limiting toxicity event and no serious adverse hemodynamic effects were seen.

CONCLUSIONS: Esmolol administration, titrated to a heart rate reduction of 15%, is feasible within 24 h of severe traumatic brain injury. The probability of dose-limiting toxicity requiring withdrawal of esmolol when using the optimized schedule is low. Trial registrationI SRCTN, ISRCTN11038397, registered retrospectively January 7, 2021 ( https://www.isrctn.com/ISRCTN11038397 ).

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Thomas M, Hayes K, White P, et al. Early Intravenous Beta-Blockade with Esmolol in Adults with Severe Traumatic Brain Injury: A Phase 2a Intervention Design Study. Neurocrit Care. 2024. PMID: 38951446. doi:10.1007/s12028-024-02029-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。